Quintiles and Population Genetics Technologies Ltd. (PGT) have entered a commercial collaboration to bring genomic testing into mainstream drug development in an effort to produce safer, more effective medicines. The two companies will jointly identify opportunities to apply large-scale genomic analyses — using samples from hundreds to thousands of individuals — to test clinical hypotheses and correlate biomarkers of disease prognosis and drug responsiveness. This approach is aimed at the ra...